Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
Go back to Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform| (NASDAQ: NTLA) | Delayed: 15.25 -0.5 (3.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.75 | 52 Week High | $30.40 | |||
| Open | $15.43 | 52 Week Low | $11.86 | |||
| Day High | $15.93 | P/E | N/A | |||
| Day Low | $15.06 | EPS | $0.00 | |||
| Volume | 3,733,412 | |||||
